Vision

We are a biopharmaceutical company dedicated to identifying, developing, and delivering breakthrough therapies for central nervous system (CNS) diseases. Our mission is to bring new hope to patients by combining innovative technologies with well-established treatments.

Our strategy is to build a robust pipeline of therapeutics targeting neuropsychiatric disorders beyond conventional approaches. Currently, we are focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need.

Hope for Patients &

Innovation for the Future

To drive innovation, our expert team, composed of both internal specialists and external thought leaders, carefully evaluates novel therapeutic opportunities. We have executed an option agreement to negotiate access to key intellectual property that we believe could revolutionize TRD treatment. If successful, this would address a critical gap in mental healthcare while unlocking substantial commercial potential.

We believe the future of mental health treatment lies in personalized medicine—tailoring therapies to the unique needs of each patient. Our mission is to bridge the gap between proven science and next-generation technology, ensuring that those suffering from severe and persistent depression finally have a path forward.

Based on clinical evidence suggesting that anesthetics could produce robust and durable antidepressant effects, we are focused on a treatment approach delivering generic intravenous anesthetics via a personalized delivery device that uses biofeedback for optimal safety and efficacy.

We are actively working toward clinical validation and regulatory approval, with the goal of bringing this much-needed therapy to market in the coming years. We remain grounded in scientific rigor and clinical evidence, and are excited about the transformational potential of our work.

JOIN US AS WE WORK TO ADVANCE THE FUTURE OF MENTAL HEALTH TREATMENT

 

Innovation with Purpose

Mental health treatment is evolving. We aim to be at the forefront—redefining what’s possible, challenging conventional paradigms, and forging a future where those who need it most finally have better options.

Strategic Vision, Proven Expertise

Our team—composed of industry leaders, researchers, and clinicians—has a track record of success in biopharmaceutical innovation. With what we believe to be a targeted and efficient approach, we have identified a potentially high-impact therapeutic opportunity in treatment-resistant depression (TRD) – an area of urgent medical need.

Transforming Potential into Progress

Our approach is designed to maximize impact while optimizing investment, to create value for stockholders and other stakeholders. Our strategy is designed to unlock substantial value while accelerating the development of breakthrough therapies.

 

 

Our board has diverse expertise identifying, developing, and gaining regulatory approval for novel assets​. Their deep industry experience has gained them strong relationships from early research to late commercialization.

We leverage a cross-disciplinary network of external advisors and experts to source, evaluate, and advance our programs. Our advisors have deep subject-matter expertise, broad industry experience, and a strong track record of bringing innovative therapies to patients.

The capital allocation decision making and financial management we use in our business is designed to enable us to continually deploy capital to the most promising opportunities.

Leadership

Regina Graul, PhD

Board of Directors

Errol De Souza, PhD, Chair Regina Graul, PhD Peter Hecht, PhD Michael Higgins Steven Hyman, MD Dina Katabi, PhD 

Contact Us

Cyclerion Therapeutics
245 First Street
Riverview II, 18th Floor
Cambridge, MA 02142

Investor Relations or Media Inquiries: IR@cyclerion.com
Partnering Inquiries: partnering@cyclerion.com

Top